Rapport's attempt to test epilepsy drug in nerve damage placed on hold by FDA

The FDA has placed a trial of Rapport Therapeutics’ epilepsy drug for a type of nerve pain on hold while the biotech tweaks the study design.

Rapport has been evaluating the TARPγ8-targeting drug, dubbed RAP-219, in a range of conditions like focal epilepsy and bipolar acute mania and as an anti-seizure medication. The biotech had submitted a request to the FDA to launch a phase 2a proof-of-concept trial in diabetic peripheral neuropathic pain (DPNP) but was “recently” notified by the agency that the request had been placed on clinical hold.